Resolution plan approved: The Mumbai bench of the National Company Law Tribunal (NCLT) approved a ₹577.24 Cr resolution plan for Arch Pharmalabs on October 15, 2026, under the Insolvency and Bankruptcy Code. The plan was submitted by a consortium led by entrepreneur Ashish Kumar and Hyderabad-based MetaX Life Sciences.
Creditor settlement: The plan includes approximately ₹567.49 Cr towards the discharge amount, alongside estimated corporate insolvency resolution process (CIRP) costs of ₹9.75 Cr. Payments are proposed within 75 days of approval.
Fresh capital and revival: The resolution proposal includes a ₹50 Cr fresh equity infusion to support the company's revival, alongside provisions for financial creditors, employees and statutory dues.
Implementation remains critical: The NCLT approval clears a key hurdle, but the proposed merger of MetaX Life Sciences into Arch Pharmalabs requires separate compliance with the applicable Companies Act procedure. Execution and business recovery remain important monitorables.
